primary antibodies against ctr1 (Proteintech)
Proteintech is a verified supplier 
90
Structured Review
Proteintech
primary antibodies against ctr1
Primary Antibodies Against Ctr1, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ctr1/mouse+anti+ctr1+monoclonal/pm39793852-118-35-46
Average 90 stars, based on 1 article reviews
Primary Antibodies Against Ctr1, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ctr1/mouse+anti+ctr1+monoclonal/pm39793852-118-35-46
Average 90 stars, based on 1 article reviews
primary antibodies against ctr1 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Incubation:Article Title: Metallothionein rescues doxorubicin cardiomyopathy via mitigation of cuproptosis. Article Snippet: Doxorubicin (DOX), a chemotherapeutic agent utilized in the management of cancer, provokes cardiotoxicity although effective remedy is lacking.. Given that DOX provokes oxidative stress and cell death in cardiomyocytes, this study evaluated the possible involvement of cuproptosis, a newly identified form of cell death, in DOXinstigated cardiac remodeling and contractile dysfunction, alongside the impact of the heavy metal scavenger metallothionein (MT) on DOX cardiomyopathy.. Cardiac-specific MT transgenic and wild-type (WT) mice were treated with DOX (5 mg/kg/wk., i.p., for 4 wks) prior to assessment of cardiac morphology and function. Fluorescence:Article Title: Metallothionein rescues doxorubicin cardiomyopathy via mitigation of cuproptosis. Article Snippet: Doxorubicin (DOX), a chemotherapeutic agent utilized in the management of cancer, provokes cardiotoxicity although effective remedy is lacking.. Given that DOX provokes oxidative stress and cell death in cardiomyocytes, this study evaluated the possible involvement of cuproptosis, a newly identified form of cell death, in DOXinstigated cardiac remodeling and contractile dysfunction, alongside the impact of the heavy metal scavenger metallothionein (MT) on DOX cardiomyopathy.. Cardiac-specific MT transgenic and wild-type (WT) mice were treated with DOX (5 mg/kg/wk., i.p., for 4 wks) prior to assessment of cardiac morphology and function. Microscopy:Article Title: Metallothionein rescues doxorubicin cardiomyopathy via mitigation of cuproptosis. Article Snippet: Doxorubicin (DOX), a chemotherapeutic agent utilized in the management of cancer, provokes cardiotoxicity although effective remedy is lacking.. Given that DOX provokes oxidative stress and cell death in cardiomyocytes, this study evaluated the possible involvement of cuproptosis, a newly identified form of cell death, in DOXinstigated cardiac remodeling and contractile dysfunction, alongside the impact of the heavy metal scavenger metallothionein (MT) on DOX cardiomyopathy.. Cardiac-specific MT transgenic and wild-type (WT) mice were treated with DOX (5 mg/kg/wk., i.p., for 4 wks) prior to assessment of cardiac morphology and function. Laser-Scanning Microscopy:Article Title: Metallothionein rescues doxorubicin cardiomyopathy via mitigation of cuproptosis. Article Snippet: Doxorubicin (DOX), a chemotherapeutic agent utilized in the management of cancer, provokes cardiotoxicity although effective remedy is lacking.. Given that DOX provokes oxidative stress and cell death in cardiomyocytes, this study evaluated the possible involvement of cuproptosis, a newly identified form of cell death, in DOXinstigated cardiac remodeling and contractile dysfunction, alongside the impact of the heavy metal scavenger metallothionein (MT) on DOX cardiomyopathy.. Cardiac-specific MT transgenic and wild-type (WT) mice were treated with DOX (5 mg/kg/wk., i.p., for 4 wks) prior to assessment of cardiac morphology and function. Staining:Article Title: Metallothionein rescues doxorubicin cardiomyopathy via mitigation of cuproptosis. Article Snippet: Doxorubicin (DOX), a chemotherapeutic agent utilized in the management of cancer, provokes cardiotoxicity although effective remedy is lacking.. Given that DOX provokes oxidative stress and cell death in cardiomyocytes, this study evaluated the possible involvement of cuproptosis, a newly identified form of cell death, in DOXinstigated cardiac remodeling and contractile dysfunction, alongside the impact of the heavy metal scavenger metallothionein (MT) on DOX cardiomyopathy.. Cardiac-specific MT transgenic and wild-type (WT) mice were treated with DOX (5 mg/kg/wk., i.p., for 4 wks) prior to assessment of cardiac morphology and function. Immunofluorescence:Article Title: Metallothionein rescues doxorubicin cardiomyopathy via mitigation of cuproptosis. Article Snippet: Doxorubicin (DOX), a chemotherapeutic agent utilized in the management of cancer, provokes cardiotoxicity although effective remedy is lacking.. Given that DOX provokes oxidative stress and cell death in cardiomyocytes, this study evaluated the possible involvement of cuproptosis, a newly identified form of cell death, in DOXinstigated cardiac remodeling and contractile dysfunction, alongside the impact of the heavy metal scavenger metallothionein (MT) on DOX cardiomyopathy.. Cardiac-specific MT transgenic and wild-type (WT) mice were treated with DOX (5 mg/kg/wk., i.p., for 4 wks) prior to assessment of cardiac morphology and function. |